Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CD5-HP2H6 | Human | PE-Labeled Human CD5 Protein, His Tag (Site-specific conjugation) | ![]() |
![]() ![]() |
|
CD5-H5253 | Human | Human CD5 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
|
CD5-H82F3 | Human | Biotinylated Human CD5 Protein, Fc,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
|
CD5-H82E5 | Human | Biotinylated Human CD5 Protein, His,Avitag™ | ![]() |
![]() ![]() |
|
CD5-H52H2 | Human | FITC-Labeled Human CD5 Protein, His Tag | ![]() |
![]() ![]() |
|
CD5-H52H5 | Human | Human CD5 Protein, His Tag | ![]() |
![]() ![]() |
5e5 of anti-CD5 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD5, His Tag (Cat. No. CD5-HP2H6) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
The purity of Biotinylated Human CD5, Fc,Avitag (Cat. No. CD5-H82F3) is more than 90% and the molecular weight of this protein is around 155-175 kDa verified by SEC-MALS.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
CD5 CAR T (CT125B) therapy ( Beijing Boren Hospital) | CD5 CAR T (CT125B); CT125B; CD5 CAR T | Phase 1 Clinical | Beijing Gao Boren Hospital Co Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
CT-125A | CT-125A; RD-125 | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Lymphoma, T-Cell, Peripheral; Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Plasmablastic Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CD5 CAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell | Details | ||
MT-101 | MT-101 | Phase 2 Clinical | Myeloid Therapeutics Inc | Lymphoma, T-Cell, Peripheral; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides | Details |
CD5 CAR-T Therapy(Xuanwu Hospital) | Phase 1 Clinical | Xuanwu Hospital Of Capital Medical University | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
This web search service is supported by Google Inc.